Journal List > J Korean Ophthalmol Soc > v.59(10) > 1103097

Baek, Kim, and Kim: Regulation of Matrix Metalloproteinase 2 Expression by an Adenosine A1 Agonist in Trabecular Meshwork Cells

Abstract

Purpose

We investigated the extent of adenosine A1 agonist-induced expression and regulation of matrix metalloproteinase 2 (MMP-2) synthesis in human trabecular meshwork cells (HTMC).

Methods

Primary HTMC cultures were exposed to 0.1 or 1.0 µM N6-cyclohexyladenosine (CHA) for 2 h in the presence or absence of an inhibitor thereof, 8-cyclopentyl-1,3-dimethylxanthine (CPT). The expression level of mRNA encoding MMP-2 was assessed via reverse transcription-polymerase chain reaction, and the levels of tissue inhibitor of metalloproteinase 2 (TIMP2) and membrane-type-1 MMP (MT1-MMP) measured by Western blotting. The permeability of the HTMC monolayer was assessed with the aid of carboxyfluorescein.

Results

CHA at 1.0 µM increased the permeability of the HTMC monolayer (p = 0.003) and CHA at both 0.1 and 1.0 µM significantly increased MMP-2 mRNA expression, which was inhibited by co-exposure to CPT (all p < 0.05). CHA increased MMP-2 activity, decreased that of TIMP2, and increased that of MT1-MMP (all p < 0.05).

Conclusions

CHA increased the permeability of the HTMC monolayer and increased MMP-2 activity, decreased TIMP2 activity, and increased MT1-MMP activity. Thus, regulation of TIMP2 and MT1-MMP expression may be involved in the adenosine A1 agonist-induced increase in MMP-2 activity.

Figures and Tables

Figure 1

Exposure to 1.0 µM N6-cyclohexyladenosine (CHA) increased the permeability of carboxyfluorescin significantly compared to control. Exposure to the 10 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT) decreased permeability significantly when co-exposed to 0.1 or 1.0 µM CHA (*). When co-exposed to CPT, 0.1 or 1.0 µM CHA decreased permeability significantly compared with exposure to CHA alone (**). Carboxyfluorescin intensity of outer chamber normalized to the mean value obtained using non-exposed control (permeability 100%). *,**p < 0.05.

jkos-59-946-g001
Figure 2

Exposure to 0.1, 1.0 µM N6-cyclohexyladenosine (CHA) increased significantly the expression of matrix metalloproteinase 2 (MMP2) mRNA with or without co-exposure to 10 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT) compared to control. Co-exposure to the 10 µM CPT with 0.1 or 1.0 µM CHA decreased the expression of MMP2 mRNA compared to exposure to CHA alone, respectively. β-actin used as internal standard. *p < 0.05.

jkos-59-946-g002
Figure 3

Exposure to 0.1, 1.0 µM N6-cyclohexyladenosine (CHA) increased significantly the activity of matrix metalloproteinase 2 with or without co-exposure to 10 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT) compared to control. GAPDH used as internal standard. *p < 0.05.

jkos-59-946-g003
Figure 4

Exposure to 1.0 µM N6-cyclohexyladenosine (CHA) decreased significantly the activity of tissue inhibitor of metalloproteinase 2 (TIMP2) with or without co-exposure to 10 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT) compared to control. Exposure to the 10 µM CPT alone did not affect the activity of TIMP2. GAPDH used as internal standard. *p < 0.05.

jkos-59-946-g004
Figure 5

Exposure to 1.0 µM N6-cyclohexyladenosine (CHA) increased significantly the activity of membrane-type-1 matrix metalloproteinase (MT1-MMP). Co-exposure to the 10 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT) with 0.1 or 1.0 µM CHA decreased the activity of MT1-MMP. GAPDH used as internal standard. *p < 0.05.

jkos-59-946-g005

Notes

This work was supported by the grant of Research Institute of Medical Science, Daegu Catholic University (2017).

Conflicts of Interest The authors have no conflicts to disclose.

References

1. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984; 91:564–579.
crossref
2. Rohen JW, Lütjen-drecoll E, Flügel C, et al. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res. 1993; 56:683–692.
3. Schmidl D, Schmetterer D, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015; 31:63–77.
crossref
4. Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs. J Ocul Pharmacol Ther. 2014; 30:85–87.
crossref
5. Zhong Y, Yang Z, Huang WC, Luo X. Adenosine, adenosine receptors and glaucoma: an updated overview. Biochimica et Biophysica Acta. 2013; 1830:2882–2890.
crossref
6. Sanka K, Maddala R, Epstein DL, Rao PV. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007; 48:2105–2114.
crossref
7. Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002; 43:3016–3020.
8. Kim JW. Comparative study of the effects of trabecular meshwork outflow drugs on the permeability and nitric oxide production in trabecular meshwork cells. Korean J Ophthalmol. 2017; 31:452–459.
crossref
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63.
crossref
10. Song J, Deng PF, Stinnett SS, et al. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 2005; 46:2424–2432.
crossref
11. Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci. 2012; 53:3092–3103.
crossref
12. Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci. 1979; 18:1043–1049.
13. Alvarado JA, Wood I, Polansky JR. Human trabecular cells. II. Growth pattern and ultrastructural characteristics. Invest Ophthalmol Vis Sci. 1982; 23:464–478.
14. Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther. 1995; 273:320–326.
15. Crosson CE. Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. Invest Ophthalmol Vis Sci. 2001; 42:1837–1840.
16. Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997; 64:979–989.
crossref
17. Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther. 2007; 320:258–265.
crossref
18. Fleischhauer JC, Mitchell CH, Stamer WD, et al. Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport. J Membrane Biol. 2003; 193:121–136.
crossref
19. Keller KE, Aga M, Bradley JM, et al. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009; 88:676–682.
crossref
20. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998; 39:2649–2658.
21. Pang IH, Helberg PE, Fleenor DL, et al. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2003; 44:3485–3493.
crossref
22. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003; 59:812–823.
crossref
23. Löffek S, Schilling O, Franzke CW. Series “matrix metalloproteinases in lung health and disease”: biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011; 38:191–208.
TOOLS
Similar articles